Skip to content

H.R. 7188 · 118th Congress (2023–2025)

Shandra Eisenga Human Cell and Tissue Product Safety Act

This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.

Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments.

The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Show official title

To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.

Expired in Senate

Derived from the legislative history, not an official disposition.

This bill’s path

319 days after it was introduced

This is H.R. 7188’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced10 months

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. John R. Moolenaar (R-MI-2)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Rep. Debbie Dingell (D-MI-6)· Original · Feb 1, 2024
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Civil actions and liability
  • Congressional oversight
  • Department of Health and Human Services
  • Health programs administration and funding
  • Health promotion and preventive care
  • Organ and tissue donation and transplantation

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. ▸ 7 committee actions · Feb 1, 2024 – Nov 22, 2024
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    4. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.

      Sources
    5. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    6. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.

      Sources
    7. Reported by committee

      Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.

      Sources
  3. Latest

    Passed House

    Congressional Record H7167–H7168

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources
  4. Expired

    Passed House → Received in Senate → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Feb 1, 2024 · Markup Sep 18, 2024 · Reported Nov 22, 2024H. Rept. 118-766
    1. Sep 18, 2024 · Markup

    1. H. Rept. 118-766 · Nov 22, 2024 · Shandra Eisenga Human Cell and Tissue Product Safety Act
  2. HouseHealthReferred Feb 2, 2024 · Markup May 16, 2024 · Reported May 16, 2024
    1. May 16, 2024 · Markup

    2. Feb 29, 2024 · Hearing

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Dec 16, 2024 · House · Considered under suspension of the rulesCongressional Record H7167–H7170

    Shandra Eisenga Human Cell and Tissue Product Safety Act

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Received in Senate
Reported in House
Engrossed in House
Titles (2)
  1. Shandra Eisenga Human Cell and Tissue Product Safety Act

    Short title, Display title · Engrossed in House, Reported in House, Introduced in House

  2. To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.

    Official title · Introduced in House